The application of 177Lu-based targeted radioligand therapy (TRT) is currently the most reported form; i.e., [68Ga]Ga-PSMA would be a considerable option to diagnose prostate cancer followed by the treatment therapy option of [177Lu]Lu-PSMA-617-TRT. This evidence concerns the gene FOLH1 and prostate cancer.